The Global Bioanalytical Testing Services Market-
Industry Trends & Forecast Report 2027
global bioanalytical testing services market was worth USD 2.7 billion in 2020
and is further projected to reach USD 6.1 billion by 2027, at a CAGR of 12.1%
during the forecast period (2021-2027). The growing demand for analytical testing for
biologics and biosimilars, small-molecule and large-molecule drugs, and the
preference for analytical outsourcing are all contributing to the market's
growth. Furthermore, pharmaceutical and biopharmaceutical companies have been increasingly investing in research and development, which in turn is
boosting the overall market growth. At the same time, rising government
practices to control pandemics like COVID-19, Ebola virus, and others are also fueling
the growth of the market. According to a report released by the World Health organization, there are 11,77,99,584 confirmed cases of COVID-19 worldwide with
Source: BlueWeave Consulting
Global Bioanalytical Testing ServicesOverview
Bioanalytical testing is used for determining the properties of drugs and metabolites in biological matrices like blood, tissue,
urine, plasma, etc. Bioanalytical
methods and assay validation allow accurate quantitation of analytes and
biomarkers in various biological matrices to assess drug safety and efficacy. This
diagnostic technique has several applications, including drug testing and
assessment, oncology, neurology, cardiology, and others. Bioanalytical testing
services assist in the evaluation of a drug's design effects, drawbacks,
suitable circumstances, and suitability for the intended treatment. Before
starting as say creation and validation, it's a good idea to learn about the
analyte's physicochemical properties.
Global Bioanalytical Testing services market Trend
Increased Number of laboratory Outsourcing Service
trend of outsourcing bioanalytical services is growing by leaps and bounds for better
resource utilization.While dedicated in-house laboratories have advanced
facilities, they may not be able to handle complex bioanalytical testing. Moreover,
on a strategic level, operating in-house laboratories can be a costly affair.
On the other hand, outsourcing the lab role decreases overhead and operational
costs owing to which business companies continue to benefit from such lab
services. Lab outsourcing helps companies and other institutions to make a
profit as it allows to trade higher fixed-costs for lower variable-costs, thereby
reducing the need for capital investment in the company and allowing instant
access to world-class analytical expertise and capabilities on a short notice
period. The aforementioned factors are significantly driving the market growth.
Rise in the R&D Expenditure in the Pharmaceutical
and Biopharmaceutical Industry
pharmaceutical industry spent a total of 136 billion dollars in 2012. In 2019,
it spent 186 billion dollars on research and development. According to PhRMA,
research and development (R&D) investment by PhRMA member companies totaled
83 billion US dollars in 2019, making the biopharmaceutical industry the most
R&D-intensive industry in the US economy. In fact, the biopharmaceutical industry spends six times as much in research and development as all other
manufacturing sectors combined.PhRMA member companies have invested nearly USD 1
trillion in the quest for and creation of new and improved drugs and cures over
the last few decades.
The regulatory authority is involved in the process at some point, usually during
the pre-clinical phase, to oversee, control, and eventually authorize the drug.
In recent years, major developments in pharmaceutical research and development
have begun to alter the R&D landscape. To cut costs, a growing number of
drug manufacturers are outsourcing large parts of R&D, mostly to clinical
research organizations, also known as contract research organizations.
The Lack of Dearth of Skilled Professionals
rising demand for skilled health care practitioners is not exclusive to The United States. According to a report published in the journal Human Resources
for Health in 2016, 80 million health care staff will be needed globally by
2030. Nevertheless, only 65 million healthcare workers are projected to be
available by 2020, leaving a global shortage of 15 million. Even though the
basic threshold for health care staff is 23 qualified professionals per 10,000
populations, 83 countries still fall short of the target. 6.6 million children
under the age of five died in the year 2012. The majority of deaths were caused
by diseases that could have been avoided or treated. Moreover, 80% of
stillbirths and 90% of maternal deaths occur in almost 58 countries. Increasing
access to quality healthcare in specific areas of the world may have a huge
effect on these findings.
Impact of COVID-19
COVID-19 pandemic has severely affected the global economy besides affecting
business operations. Due to the high infection rates and adverse impact on
public health systems, various countries had to enforce nationwide lockdowns
which had a major impact on industrial supply chains, trade, and related
bioanalytical testing services also saw a downfall in the market due to
COVID-19. Moreover, limited access to clinics, combined with social distancing
norms and complete lockdown declared by several countries resulted in a
slow-down in patient flow and referral, which in turn has impacted the market
growth. During the COVID-19 epidemic, cancer screenings fell sharply. Repeated
screenings for cervical cancer went down by 68% across the USA in the first 15
weeks of 2020, while breast cancer checking went down by 17%, with more
significant declines in areas where the outbreak was the sturdiest.
Global Bioanalytical Testing services market: By
on end-user, the global bioanalytical testing services market is grouped into
pharmaceutical and biopharmaceutical companies, contract development and
manufacturing organizations, and contract research organizations. In 2020, the
pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the bioanalytical testing services market. Pharmaceutical
companies nowadays are increasingly outsourcing early-stage development,
clinical, and laboratory testing services to increase profit margins, avoid
high capital expenditure, and reduce the time it takes to validate processes
and services, which accounts for a significant share of this segment.
Source: BlueWeave Consulting
Global Bioanalytical Testing Services Market: By
on molecule size, the global bioanalytical testing services market is
fragmented into small molecules and large molecules. Since they play such an important role in the production of generic versions of branded drugs, the
small molecule testing services sub-segment is expected to have the largest
revenue share in the bioanalytical testing services industry.These bioanalytical
testing results plays a significant role in demonstrating the efficacy of
simulating generic drug release profiles, resulting in the segment's
Global Bioanalytical Testing services market: Regional
the global bioanalytical testing services market is categorized into North
America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin
America. North America leads the global bioanalytical testing services industry
and is projected to lead the overall industry during the forecast period. The
growth is mainly driven by the presence of major industry players in the region,
the increasing number of pharmaceutical and biopharmaceutical companies,
technological developments, and government initiatives that have increased
North America's demand for bioanalytical testing services.
The bioanalytical testing services market's high
growth potential has drawn a slew of new entrants, creating a lucrative
opportunity. The emergence of new entrants has resulted in more healthy
competition among long-established service providers. In the present scenario,
many contract development and manufacturing organizations (CDMOs), which have
analytical capabilities to support their manufacturing activities and
development, are offering analytical services and some guided expertise to
other laboratories as well.
Some of the key players include Charles River
laboratories, Medpace, Wuxi Apptec, Eurofins Scientific, Iqvia Inc., Sgs Sa, Laboratory
Corporation of America Holdings, Intertek Group Plc, Pra Health Sciences,
Syneos Health, Icon Plc, Frontage Labs, and other prominent players. In order to
improve their production capability, product portfolio, and provide competitively
differentiation, companies are increasingly participating in acquisitions,
alliances, and mergers.
17 February 2021, Charles River Laboratories announced
the acquisition of Cognate BioServices, a premier cell and gene therapy
contract development and manufacturing organization (CDMO), and Cobra
Biologics, its gene therapy division. The planned acquisition will establish
Charles River as a leading scientific partner for cell and gene therapy
development, testing, and manufacturing, providing clients with an integrated solution from early research and discovery through CGMP production.
10 February 2020, SGS SA announced that its
Center of Excellence for Biosafety laboratory will offer Good Manufacturing
Practice (GMP)-compliant vaccine testing solutions for coronavirus which is likely
to help in the detection of novel coronavirus with effective testing solutions.
of the Report
Historical data – 2017-2020
Base Year – 2020
Forecast – 2021 – 2027
Revenue in USD Billion
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Japan, South
Korea, China, India, UAE, South Africa, Saudi Arabia
By test type, application,
molecule size, end-users, and region
Key Players for the market are Charles River, Medpace, Wuxi Apptec, Eurofins
Scientific, Iqvia Inc., Sgs Sa, Laboratory Corporation of America Holdings,
Intertek Group Plc, Pra Health Sciences, Syneos Health, Icon Plc, Frontage
Labs, Other Prominent Players
By Test Type
Viral PCR Assays
Immunogenicity & Neutralizing Antibodies
By Molecule Size
and Biopharmaceutical Companies
Development and Manufacturing Organizations
Ø The Asia-Pacific
Ø North America
Ø The Middle East & Africa
Ø Latin America
is the current size of the global bioanalytical testing services market?
Answer: The global bioanalytical testing services market
has reached USD 2.7 billion in 2020.
are the major factors driving the growth of the global bioanalytical testing services market?
major factors driving the growth of the global bioanalytical testing services the market is the increased number of laboratory outsourcing services and increasing
R&Dinvestments in the pharmaceutical and biopharmaceutical industry.
are the key players in the global bioanalytical testing services market?
Answer: The key
players in the global bioanalytical testing services market are Charles River
Laboratories, Medpace, Wuxi Apptec, Eurofins Scientific, Iqvia Inc., Sgs Sa,
Laboratory Corporation of America Holdings, Intertek Group Plc, Pra Health
Sciences, Syneos Health, Icon Plc, Frontage Labs, Other Prominent Players, and
other prominent players.
Which end-user accounted for the largest share in the
global bioanalytical testing services market?
Answer: Pharmaceutical and Biopharmaceutical Companies by
end-user accounted for the largest share in the global bioanalytical testing
region is growing at a higher rate in the global bioanalytical testing services market?
Answer: North America is growing at a higher rate in
the global bioanalytical testing services market.